Get the Stockscreener App
13.58
8.12%
-1.1422
Biohaven Ltd stock is traded at $13.58, with a volume of 785.16K.
It is down -8.12% in the last 24 hours and down -6.98% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$14.72
Open:
$13.525
24h Volume:
785.16K
Relative Volume:
0.26
Market Cap:
$2.07B
Revenue:
-
Net Income/Loss:
$-647.68M
P/E Ratio:
-2.3947
EPS:
-5.67
Net Cash Flow:
$-594.49M
1W Performance:
-14.72%
1M Performance:
-6.98%
6M Performance:
+31.69%
1Y Performance:
-3.46%
1-Day Range:
$13.26
$13.84
1-Week Range:
$14.33
$15.80
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
13.70 | 2.22B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
516.90 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.68 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.97 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
132.00 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.33 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
US FDA pauses new enrollment in Biohaven's epilepsy drug trials - Reuters
Biohaven stock tumbles after pausing trial enrollment By Investing.com - Investing.com Australia
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold - Investing.com Canada
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com India
Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise? - simplywall.st
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
Biohaven Pharma stock falls after RBC Capital downgrade By Investing.com - Investing.com India
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - marketscreener.com
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven Pharma stock falls after RBC Capital downgrade - Investing.com
BHVN Downgraded by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk - marketscreener.com
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target - Yahoo Finance
Why is Biohaven Pharmaceutical stock sliding today? By Investing.com - Investing.com Canada
RBC Capital downgrades Biohaven Pharma stock rating on valuation By Investing.com - Investing.com South Africa
Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile? - simplywall.st
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet - Yahoo Finance
With an ion the bottom line, Biohaven signs SK epilepsy deal - BioWorld News
Biohaven (BHVN) Is Up 11.3% After Out-Licensing Kv7 Platform To SK Biopharm For Up To $795M - webull.com
Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal? - simplywall.st
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Why Biohaven Stock Was Rocking the Market This Week - Yahoo Finance
Biohaven advances key drug trials and secures $350M deal with SK Biopharmaceuticals - Pluang
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels - Seeking Alpha
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - Yahoo Finance
Why Biohaven Ltd. (BHVN) Stock Is Up Today - Quiver Quantitative
Biohaven Ltd. And SK Biopharmaceuticals Co., Ltd. Enter Into Global Licensing Agreement For Kv7 Ion Channel Platform And Opakalim - marketscreener.com
Biohaven stock surges 7% on SK Biopharmaceuticals deal By Investing.com - Investing.com Australia
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M - StreetInsider
SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal - AllSci
Biohaven stock surges 7% on SK Biopharmaceuticals deal - Investing.com
Biohaven (NYSE: BHVN) offloads epilepsy drug costs in rich global licensing pact - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Biohaven, Yale win $4M judgment in trade secret case By Investing.com - Investing.com Nigeria
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University - PR Newswire
Biohaven’s epilepsy drug deal could bring $400 million in cash from SK Biopharmaceuticals - Stock Titan
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement? - Sahm
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses - Sahm
Price to earnings forward of Biohaven Ltd. – NYSE:BHVN - TradingView
HC Wainwright Decreases Earnings Estimates for Biohaven - MarketBeat
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biohaven (BHVN) Pulls Back 1.4% as Shares Approach Key $13.91 Support ZoneChannel Breakout - vinanet.vn
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP - MarketBeat
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)? - Sahm
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands - simplywall.st
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - Yahoo Finance
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven - Stock Titan
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):